It has been reported that bile acid signaling and metabolism and bile acid homeostasis are disrupted in patients with MAFLD, and that drugs targeting the farnesoid X receptor (FXR)-fibroblast growth factor 19 axis or bile acid conjugates might be beneficial in the treatment of NASH (8–10). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.